Clinical trials: Primary Lateral Sclerosis
- Condition Primary Lateral Sclerosis
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Amyotrophic Lateral Sclerosis (ALS)
A First in Human Study of ORT247 in Healthy Volunteers
This is a single center, double-blinded, randomized, placebo controlled single ascending dose clinical study, with the primary purpose of evaluating the safety, tolerability, pharmacokinetics (PK), and immunohistochemistry of…
- Trial name
- NCT06769620
- Testing
- ORT247
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Orthogonal Neuroscience Inc.
Parkinson Disease Psychosis, Amyotrophic Lateral Sclerosis (ALS)
A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics and pharmacodynamics of oral doses of FB418 in healthy adult subjects and healthy elderly subjects.
- Trial name
- NCT05995782
- Testing
- FB418
- Where
- South Korea
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- 1ST Biotherapeutics, Inc.
Amyotrophic Lateral Sclerosis (Healthy Volunteers)
A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)
Part 1: This is an open label, balanced randomized, single dose, 2-sequence, 2-period (period 1 and period 2), 2-treatment crossover (between Treatment A and Treatment B for Part 1), study part to determine the relative…
- Trial name
- NCT05797701
- Testing
- SAR443820
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Sanofi
ALS, ALS (Amyotrophic Lateral Sclerosis)
Systems Biology of Amyotrophic Lateral Sclerosis (ALS)
The goal of this observational study is to identify molecular features in multiple clinical samples and/or the patient environment that are associated with ALS.
- Trial name
- NCT07007390
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Viome
Healthy Volunteers
A Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects
To evaluate the PK, safety and tolerability of orally administered NPT520-34 in healthy subjects at single and multiple doses that may be therapeutically relevant.
- Trial name
- NCT03954600
- Testing
- NPT520-34 (125 mg)
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Neuropore Therapies Inc.
Amyotrophic Lateral Sclerosis
Dexpramipexole and Cimetidine Drug Drug Interaction (DDI)
This study will assess the effect of cimetidine on the pharmacokinetics (PK) of dexpramipexole in healthy volunteer and evaluate the safety and tolerability of dexpramipexole when given with or without cimetidine.
- Trial name
- NCT01536249
- Testing
- Dexpramipexole, Cimetidine plus Dexpramipexole
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Knopp Biosciences
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram
ALS (Amyotrophic Lateral Sclerosis)
This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling
Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive neurodegenerative disorder characterized by loss of upper and lower motor neurons, leading to muscle weakness, respiratory decline, and eventual mortality.
- Trial name
- NCT07321860
- Testing
- Galunisertib + Nerandomilast Combination
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Gipfel Life Sciences GmbH
Amyotrophic Lateral Sclerosis (Healthy Volunteers)
Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants
This is a Phase 1, single-center study conducted in 2 parts: Part 1a, single ascending dose (SAD-TDU16519): Double-blind, randomized, placebo-controlled sequential ascending single oral doses including up to 6 cohorts.
- Trial name
- NCT05795907
- Testing
- SAR443820
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Sanofi
Amyotrophic Lateral Sclerosis
Study of SPG302 in Healthy Volunteers and ALS Participants
The first-in-human Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SPG302 in healthy volunteers and ALS participants
- Trial name
- NCT05882695
- Testing
- SPG302
- Where
- 4 sites in Australia
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Spinogenix
ALS (Amyotrophic Lateral Sclerosis)
Safety and Feasibility of the EyeControl Device
The EyeControl device is an eye movement-based communication device in the form of wearable glasses with connected infrared cam-era that tracks the pupil and translates blinks and movements into commands.This study is aimed to…
- Trial name
- NCT02891629
- Testing
- EyeControl device
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Eyefree Assisting Communication Ltd
Amyotrophic Lateral Sclerosis
Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Participants
This study will evaluate the pharmacokinetics and safety of GDC-0134 in healthy female volunteers of non-childbearing potential.
- Trial name
- NCT03237741
- Testing
- Reference capsule GDC-0134, Prototype capsule GDC-0134, rabeprazole
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy
A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of TBN
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (i.e. how study drug is taken up by the body) of TBN in healthy participants.
- Trial name
- NCT04667013
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Guangzhou Magpie Pharmaceuticals Co., Ltd.
Amyotrophic Lateral Sclerosis (ALS)
Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance Myography
The purpose of this protocol is to test a new Electrical Impedance Myography (EIM) device and study its reliability and ability to differentiate ALS patients from healthy controls.
- Trial name
- NCT01803386
- Testing
- EIM Measurements
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Skulpt, Inc.
Healthy Volunteers
A Study of VRG50635 in Healthy Volunteers
The primary objectives of this study are to investigate the safety and tolerability of VRG50635 and to determine how VRG50635 is absorbed by the body.
- Trial name
- NCT06286475
- Testing
- VRG50635
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Verge Genomics
Alzheimer's Disease, Multiple Sclerosis
A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery
The purpose of this research project is to collect and store blood samples and clinical data. Researchers can then use the stored samples in future studies.
- Conditions
- Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease, Huntington's Disease
- Trial name
- NCT01592552
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Amyotrophic Lateral Sclerosis (ALS)
Safety, Tolerability, and Pharmacokinetics of FHND1002 Granules in Healthy Adults
The goal of this clinical trial is to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of FHND1002 granules in healthy adult volunteers.
- Trial name
- FHND1002-Ⅰ (NCT06782958)
- Testing
- 50mg FHND1002, 100mg FHND1002, 150 mg FHND1002
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Amyotrophic Lateral Sclerosis
To Determine the Maximum Tolerated Dose (MTD) of HK-001 in Healthy Volunteers
Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts. After single dose administration, followed by an independent Data and Safety Monitoring Board (DSMB) meeting…
- Trial name
- NCT03651349
- Testing
- HK-001
- Where
- Taiwan
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Everfront Biotech Co., Ltd.
Amyotrophic Lateral Sclerosis, Sporadic, Amyotrophic Lateral Sclerosis
ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach
RNALS is a multicentre, transversal, diagnostic and non-interventional study carried out in ALS reference centers; in order to identify a diagnostic signature for Amyotrophic Lateral Sclerosis by analyzing of coding and…
- Trial name
- RNALS (NCT05928416)
- Testing
- Saliva sample
- Where
- 19 sites in France
- Volunteers
- 653 people, healthy volunteers welcome
- Sponsor
- ZIWIG
Amyotrophic Lateral Sclerosis
Dexpramipexole SAD/MAD Study
This Phase 1 study will explore the safety, tolerability, and pharmacokinetics of single doses ranging from 300 to 600 mg and multiple daily doses ranging from 225 mg to 300 mg BID dexpramipexole in healthy volunteers.
- Trial name
- NCT01449578
- Testing
- Dexpramipexole
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Knopp Biosciences